414 related articles for article (PubMed ID: 1639933)
1. Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer.
Burmeister LA; Goumaz MO; Mariash CN; Oppenheimer JH
J Clin Endocrinol Metab; 1992 Aug; 75(2):344-50. PubMed ID: 1639933
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of carboxyterminal cross-linked telopeptide of type I collagen (ICTP) in the differential diagnosis of the syndromes of inappropriate secretion of TSH.
Persani L; Preziati D; Matthews CH; Sartorio A; Chatterjee VK; Beck-Peccoz P
Clin Endocrinol (Oxf); 1997 Aug; 47(2):207-14. PubMed ID: 9302396
[TBL] [Abstract][Full Text] [Related]
3. Changes in serum triiodothyronine, thyroxine, and thyrotropin during treatment with thyroxine in severe primary hypothyroidism.
Maeda M; Kuzuya N; Masuyama Y; Imai Y; Ikeda H
J Clin Endocrinol Metab; 1976 Jul; 43(1):10-7. PubMed ID: 947930
[TBL] [Abstract][Full Text] [Related]
4. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.
Wang PW; Wang ST; Liu RT; Chien WY; Tung SC; Lu YC; Chen HY; Lee CH
J Clin Endocrinol Metab; 1999 Dec; 84(12):4549-53. PubMed ID: 10599717
[TBL] [Abstract][Full Text] [Related]
5. Clinical experience with sensitive thyrotropin measurements: diagnostic and therapeutic implications.
Bayer MF; Kriss JP; McDougall IR
J Nucl Med; 1985 Nov; 26(11):1248-56. PubMed ID: 3840528
[TBL] [Abstract][Full Text] [Related]
6. Comparison of conventional L-thyroxine withdrawal and moderate hypothyroidism in preparation for whole-body 131-I scan and thyroglobulin testing.
Marturano I; Russo M; Spadaro A; Latina A; Malandrino P; Regalbuto C
J Endocrinol Invest; 2015 Sep; 38(9):1017-22. PubMed ID: 26070652
[TBL] [Abstract][Full Text] [Related]
7. Serum Thyroid Hormone Balance in Levothyroxine Monotherapy-Treated Patients with Atrophic Thyroid After Radioiodine Treatment for Graves' Disease.
Ito M; Kawasaki M; Danno H; Kohsaka K; Nakamura T; Hisakado M; Yoshioka W; Kasahara T; Kudo T; Nishihara E; Fukata S; Nishikawa M; Nakamura H; Miyauchi A
Thyroid; 2019 Oct; 29(10):1364-1370. PubMed ID: 31411123
[No Abstract] [Full Text] [Related]
8. Free thyroxine, free triiodothyronine, and thyrotropin concentrations in hypothyroid and thyroid carcinoma patients receiving thyroxine therapy.
Liewendahl K; Helenius T; Lamberg BA; Mähönen H; Wägar G
Acta Endocrinol (Copenh); 1987 Nov; 116(3):418-24. PubMed ID: 3687325
[TBL] [Abstract][Full Text] [Related]
9. Changes in circulating thyroid hormone levels and systolic time intervals in acute hypothyroidism.
Price DE; O'Malley BP; Northover B; Rosenthal FD
Clin Endocrinol (Oxf); 1991 Jul; 35(1):67-9. PubMed ID: 1889141
[TBL] [Abstract][Full Text] [Related]
10. Seasonal variation of serum thyrotropin concentration and thyrotropin response to thyrotropin-releasing hormone in patients with primary hypothyroidism on constant replacement dosage of thyroxine.
Konno N; Morikawa K
J Clin Endocrinol Metab; 1982 Jun; 54(6):1118-24. PubMed ID: 6804476
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of the optimal thyroxine dose with the TRH test for replacement and suppression therapy].
Erne P; Staub JJ; Althaus B; Fleig Y; Girard J
Schweiz Med Wochenschr; 1983 Dec; 113(50):1922-3. PubMed ID: 6420884
[TBL] [Abstract][Full Text] [Related]
12. Normal thyroxine and elevated thyrotropin concentrations: evolving hypothyroidism or persistent euthyroidism with reset thyrostat.
Kabadi UM; Cech R
J Endocrinol Invest; 1997 Jun; 20(6):319-26. PubMed ID: 9294777
[TBL] [Abstract][Full Text] [Related]
13. Thyrotropin secretion in thyrotoxic and thyroxine-treated patients: assessment by a sensitive immunoenzymometric assay.
Spencer CA; Lai-Rosenfeld AO; Guttler RB; LoPresti J; Marcus AO; Nimalasuriya A; Eigen A; Doss RC; Green BJ; Nicoloff JT
J Clin Endocrinol Metab; 1986 Aug; 63(2):349-55. PubMed ID: 3088021
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the nocturnal serum thyrotropin (TSH) surge, as assessed by TSH ultrasensitive assay, in patients receiving long term L-thyroxine suppression therapy and in patients with various thyroid disorders.
Bartalena L; Martino E; Falcone M; Buratti L; Grasso L; Mammoli C; Pacchiarotti A; Aghini-Lombardi F; Balzano S; Pinchera A
J Clin Endocrinol Metab; 1987 Dec; 65(6):1265-71. PubMed ID: 3680483
[TBL] [Abstract][Full Text] [Related]
15. Response to thyrotropin releasing hormone: an objective criterion for the adequacy of thyrotropin suppression therapy.
Hoffman DP; Surks MI; Oppenheimer JH; Weitzman ED
J Clin Endocrinol Metab; 1977 May; 44(5):892-901. PubMed ID: 404309
[TBL] [Abstract][Full Text] [Related]
16. Triiodothyronine levels in athyreotic individuals during levothyroxine therapy.
Jonklaas J; Davidson B; Bhagat S; Soldin SJ
JAMA; 2008 Feb; 299(7):769-77. PubMed ID: 18285588
[TBL] [Abstract][Full Text] [Related]
17. Defective thyroidal iodine concentration in protein-calorie malnutrition.
Gaitan JE; Mayoral LG; Gaitan E
J Clin Endocrinol Metab; 1983 Aug; 57(2):327-33. PubMed ID: 6408112
[TBL] [Abstract][Full Text] [Related]
18. TSH suppression by octreotide in differentiated thyroid carcinoma.
Maini CL; Sciuto R; Tofani A
Clin Endocrinol (Oxf); 1994 Mar; 40(3):335-9. PubMed ID: 8187297
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
[TBL] [Abstract][Full Text] [Related]
20. Degree of thyrotropin suppression in differentiated thyroid cancer without recurrence or metastases.
Kamel N; Güllü S; Dağci Ilgin S; Corapçioğlu D; Tonyukuk Cesur V; Uysal AR; Başkal N; Erdoğan G
Thyroid; 1999 Dec; 9(12):1245-8. PubMed ID: 10646665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
